Treatment of the 2,6-diiminopyridine ligand 2,6-{[2,6-(i-Pr) 2 C 6 H 3 ]N C(CH 3 )} 2 (C 5 H 3 N) with 2 equiv of Me 3 SiCH 2 Li afforded the corresponding {[2,6-{[2,6-(i-Pr) 2 C 6 H 3 ]N-C (CH 2 )} 2 (C 5 H 3 N)] 2 - ( 1 ) dianion via deprotonation of the two methyl groups attached to the two imine functions. Reaction of 1 with NdCl 3 (THF) 3 yielded {[2,6-{[2,6-(i-Pr) 2 C 6 H 3 ]N-C (CH 2 )} 2 (C 5 H 3 N)]Nd(THF)}(μ-Cl) 2 [Li(THF) 2 ]·0.5(hexane) ( 2a ), whose recrystallization from DME gave the corresponding ionic {[2,6-{[2,6-(i-Pr) 2 C 6 H 3 ]N-C (CH 2 )} 2 (C 5 H 3 N)]NdCl 2 (DME)}{Li(DME) 3 ]( 2b ). With the exception of the reaction with (allyl)MgBr, which proceeded readily with 2b to form the allyl derivative {[2,6-{[2,6-(i-Pr) 2 C 6 H 3 ]N-C (CH 2 )} 2 (C 5 H 3 N)]Nd(η 3 -C 3 H 5 )Br}{Li(DME) 3 } ( 3 ), compounds 2a, b are not suitable starting substrates for further alkylation reactions. A viable synthetic strategy for the preparation of alkyl derivatives of 2 consisted instead of the pretreatment of NdCl 3 (THF) 3 with RLi [R = Me 3 SiCH 2, CH 3 ] at low T followed by treatment with either the diimine ligand or 1 . According to this procedure, the terminally bound alkyl derivative [2,6-{[2,6-(i-Pr) 2 C 6 H 3 ]N-C (CH 2 )} 2 (C 5 H 3 N)]Nd[CH 2 Si (CH 3 ) 3 ](THF) ( 4 ) was prepared and subsequently crystallographically characterized. The same synthetic procedure with MeLi afforded {[2,6-{[2,6-(i-Pr) 2 C 6 H 3 ]N-C (CH 2 )} 2 (C 5 H 3 N)]Nd}(μ-CH 3 ) 2 [Li(THF) 2 ] ( 5 ) and {[2,6-{[2,6-(i-Pr) 2 C 6 H 3 ]N-C (CH 2 )} 2 (C 5 H 3 N)]Nd}(μ-Cl)(μ-X)[Li (THF) 2 ] ( 6 ) [X = Cl 53%, Me 47%] depending on the MeLi/Nd ratio. Both 5 and 6 as well as 2a are potent catalysts for the cis -polymerization of butadiene.
No takes yet. Share an insight, caveat, or question.
Sugiyama et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: